Skip to main content
SpringerLink
Log in

RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum

  • Published:
Journal of Zhejiang University SCIENCE B Aims and scope Submit manuscript

Abstract

Objective

To evaluate the predictive values of gene expressions of ribonucleotide reductase M1 (RRM1) and breast cancer susceptibility gene 1 (BRCA1) in peripheral blood from Chinese patients with non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum.

Methods

Forty Chinese patients with advanced NSCLC were recruited and received gemcitabine 1 200 mg/m2 on Days 1 and 8 plus carboplatin AUC 5 on Day 1. RRM1 and BRCA1 expression levels in peripheral blood were detected by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Kaplan-Meier survival curve and log-rank test were performed to evaluate the correlation between gene expression and overall survival for these subjects.

Results

No correlation was observed between gene expression of RRM1 and that of BRCA1 (P>0.05), but there was a strong correlation between the expression of RRM1 and the response to chemotherapy (P=0.003). Subjects with low RRM1 expression levels in peripheral blood had longer survival time than those with high RRM1 expression levels (16.95 vs. 12.76 months, log-rank 3.989, P=0.046). However, no significant association between BRCA1 expression levels and survival time was found (16.80 vs. 13.77 months, log-rank 0.830, P=0.362).

Conclusions

Patients with low RRM1 expression levels in peripheral blood have a greater response to chemotherapy and longer survival time. Advanced NSCLC patients with low RRM1 expression levels may benefit from gemcitabine plus platinum therapy. RRM1 mRNA expression in peripheral blood could be used to predict the prognosis of NSCLC treated by gemcitabine and platinum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K.D., Danenberg, P.V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al., 2006. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol., 17(12):1818–1825. [doi:10.1093/annonc/mdl300]

    Article  PubMed  CAS  Google Scholar 

  • Davidson, J.D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L.M., Slapak, C.A., 2004. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res., 64(11):3761–3766. [doi:10.1158/0008-5472.CAN-03-3363]

    Article  PubMed  CAS  Google Scholar 

  • Dong, S., Guo, A.L., Chen, Z.H., Wang, Z., Zhang, X.C., Huang, Y., Xie, Z., Yan, H.H., Cheng, H., Wu, Y.L., 2010. RRM1 single nucleotide polymorphism −37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J. Hematol. Oncol., 3(1):10. [doi:10.1186/1756-8722-3-10]

    Article  PubMed  Google Scholar 

  • Gautam, A., Li, Z.R., Bepler, G., 2003. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene, 22(14):2135–2142. [doi:10.1038/sj.onc.1206232]

    Article  PubMed  CAS  Google Scholar 

  • Goan, Y.G., Zhou, B., Hu, E., Mi, S., Yen, Y., 1999. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res., 59(17):4204–4207.

    PubMed  CAS  Google Scholar 

  • Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nunez, L., et al., 2004. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15(8):1194–1203. [doi:10.1093/annonc/mdh319]

    Article  PubMed  CAS  Google Scholar 

  • Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M.J., 2007. Cancer statistics, 2007. CA Cancer J. Clin., 57(1): 43–66. [doi:10.3322/canjclin.57.1.43]

    Article  PubMed  Google Scholar 

  • Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., Harkin, D.P., 2003. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res., 63(19):6221–6228.

    PubMed  CAS  Google Scholar 

  • Quinn, J.E., James, C.R., Stewart, G.E., Mulligan, J.M., White, P., Chang, G.K., Mullan, P.B., Johnston, P.G., Wilson, R.H., Harkin, D.P., 2007. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin. Cancer Res., 13(24):7413–7420. [doi:10.1158/1078-0432.CCR-07-1083]

    Article  PubMed  CAS  Google Scholar 

  • Rosell, R., Scagliotti, G., Danenberg, K.D., Lord, R.V., Bepler, G., Novello, S., Cooc, J., Crino, L., Sanchez, J.J., Taron, M., et al., 2003. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 22(23):3548–3553. [doi:10.1038/sj.onc.1206419]

    Article  PubMed  CAS  Google Scholar 

  • Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al., 2004a. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res., 10(4):1318–1325. [doi:10.1158/1078-0432.CCR-03-0156]

    Article  PubMed  CAS  Google Scholar 

  • Rosell, R., Felip, E., Taron, M., Majo, J., Mendez, P., Sanchez-Ronco, M., Queralt, C., Sanchez, J.J., Maestre, J., 2004b. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res., 10(12 Pt 2):4215s–4219s. [doi:10.1158/1078-0432.CCR-040006]

    Article  PubMed  CAS  Google Scholar 

  • Rosell, R., Skrzypski, M., Jassem, E., Taron, M., Bartolucci, R., Sanchez, J.J., Mendez, P., Chaib, I., Perez-Roca, L., Szymanowska, A., et al., 2007. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One, 2(11):e1129. [doi:10.1371/journal.pone.0001129]

    Article  PubMed  Google Scholar 

  • Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M.S., Queralt, C., Majo, J., Sanchez, J.M., Sanchez, J.J., et al., 2004. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet., 13(20):2443–2449. [doi:10.1093/hmg/ddh260]

    Article  PubMed  CAS  Google Scholar 

  • Wang, L.R., Wu, X.H., Huang, M.Z., Cai, J., Xu, N., Liu, J., 2007a. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 60(2):211–218. [doi:10.1007/s00280-006-0363-x]

    Article  PubMed  CAS  Google Scholar 

  • Wang, L.R., Huang, M.Z., Zhang, G.B., Xu, N., Wu, X.H., 2007b. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 60(4):601–607. [doi:10.1007/s00280-007-0504-x]

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Lin-run Wang, Guo-bing Zhang, Jun Li & Yang Wang

  2. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Jian Chen & Ming-wei Li

  3. Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Nong Xu

  4. Clinical Laboratory, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Jian-zhong Shen Tu

Authors
  1. Lin-run Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guo-bing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming-wei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jian-zhong Shen Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Guo-bing Zhang or Jian-zhong Shen Tu.

Additional information

Project supported by the Science and Technology Planning Project of Zhejiang Province (No. 2009C33165) and the Medical Science Research Fund Scheme of Zhejiang Province (No. 2008A060), China

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Lr., Zhang, Gb., Chen, J. et al. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. J. Zhejiang Univ. Sci. B 12, 174–179 (2011). https://doi.org/10.1631/jzus.B1000197

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1000197

Key words

CLC number

Search

Navigation